DUBLIN, Dec. 13, 2023 /PRNewswire/ — The “Melanoma Therapeutics: Global Markets” report has been added to ResearchAndMarkets.com’s offering.
The global market for melanoma treatment was estimated to reach $6.8 billion in 2022 and is expected to reach $12.1 billion through 2028, growing at a CAGR of 10.2% during the forecast period. The melanoma treatment market is segment based on type of treatment, type of therapeutics, treatment by stage and by region. Major players in the market include Merck & Co., Bristol Myers Squibb and Novartis. Apart from the major players there are also small biotech companies such as Erasca, HUYABIO International and IO Biotech that have promising drug candidates in the pipeline, which should push market growth during the forecast period.
The North American region accounted for the highest share of the global market, followed by Europe. In the North American and European regions, key growth factors include increasing prevalence of melanoma, high healthcare expenditures, increasing number of drug approvals, strong pipelines, increasing public awareness and government support. Based on type of treatment, therapeutics accounted for the highest market share in 2022. Based on stage, localized stage accounted for the highest market share in 2022. In the therapeutics segment, immunotherapies accounted for the highest market share in 2022.
The majority of melanoma patients are diagnosed in the localized stage of the disease, for which surgery is the mainstay of treatment. Since 2011, agents such as immunotherapies and targeted therapies have been approved to treat advanced melanoma, increasing patient survival rates. Five-year overall survival (OS) rates for metastatic melanoma have increased substantially, from less than 10% before 2011, to 40% to 50% post-approval of novel therapies. Before novel therapies were introduced, patients received standard chemotherapy, for which the survival rates are than 5% to 6%. Thus, the development of novel treatments, in particular the immunomodulating monoclonal antibodies or the immune-checkpoint inhibitors (anti-CTLA-4, anti-PD-1/PD-L1) and small molecule-targeted therapies (BRAF and MEK inhibitors), has revolutionized the prognosis for patients with advanced melanoma. These targeted and immunotherapies have been approved for use either as monotherapy or as combination therapies with better outcomes.
Despite the efficacy of cancer immunotherapy targeting CTLA4 and PD1/PDL1, a considerable portion of patients (nearly 40%), including those with melanoma, did not respond to immunotherapy. As a result, attention has turned towards exploring different inhibitory targets and suppressive mechanisms present within the tumor microenvironment.
The pipeline for melanoma is strong, with first-in-class molecules that have novel targets. The pipeline also focuses on personalized treatment approaches such as cell therapy and vaccines which aim at treating the disease and reduce the recurrence.
The following market factors are increasing, which is boosting market growth: prevalence of melanoma, strategic initiatives, technological advancements, product launches, early detection tools, patient advocacy groups and public awareness. However, factors restricting market growth include the high cost of treatment, stringent regulations and resistance or poor response to therapies.
The Report Includes
30 data tables and 18 additional tables
An overview of the global market for melanoma treatment
Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Description of various treatment options such as chemotherapy, surgical resection, immunotherapy, and targeted therapies; and various treatment approaches for the betterment of patient’s overall health
A look at the advancements in the genetic profiling of melanocytes and identification of novel molecules that involved in melanoma’s development
Information on new potential therapeutic target discovery; and description of novel immune checkpoint inhibitors, adoptive cell therapy and engineered TCR therapy
Coverage of innovation, technological advancements, and the launch of novel products from market players
Detailed analysis of the regulatory framework and policies and product pipeline of the industry, and discussion on ESG challenges in the pharmaceutical industry and ESG practices in the melanoma treatment market
Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
Comprehensive company profiles of the leading players of the industry, including Amgen, Roche, Merck & Co., Pfizer Inc., BMS, and Novartis AG
Key Topics Covered:
Chapter 1: Introduction
Chapter 2: Summary and Highlights
Chapter 3: Market and Technology Background
Risk Factors, Causes and Prevention
Symptoms
Pathophysiology and Clinical Subtypes
Prognosis
Epidemiology
Diagnosis
Biopsy
Laboratory Tests
Blood Tests
Imaging Tests
Treatment
Immunotherapy
PD-1 and PD-L1 Inhibitors
CTLA-4 inhibitors
LAG-3 Inhibitors
Interleukin-2 (IL-2, Proleukin)
Virus Therapy
BRAF inhibitors:
MEK Inhibitors
Chapter 4: Market Dynamics
Market Factors
Market Drivers
Increasing Prevalence of Melanoma
Technological Advancements and Product Launches
Strategic Initiatives
Developments in Early Detection Tools
Patient Advocacy Groups and Awareness
Market Restraints
High Cost of Treatment
Stringent Regulations
Resistance to Therapies
Market Opportunities
Chapter 5: Market Breakdown by Type
Surgery
Wide Excision
Mohs Surgery
Amputation
Lymph Node Dissection
Therapeutics
Therapeutics by Type
Radiation Therapy
Chapter 6: Market Breakdown by Disease Stage
Localized Disease
Regional Disease
Distant Disease
Chapter 7: Market Breakdown by Region
Chapter 8: Sustainability: An ESG Perspective
ESG Challenges in the Pharmaceutical Industry
ESG Practices in the Market for Melanoma Therapeutics
Case Study
Research Viewpoint
Chapter 9: Emerging Technologies/ Developments
Novel Immune Checkpoint Inhibitors
Adoptive Cell Therapy
Engineered TCR Therapy
Vaccines
Targeted Therapy
Chapter 10: Regulatory Landscape and Pipeline Analysis
Chapter 11: Patent Analysis
Chapter 12: Competitive Landscape
Chapter 13: Company Profiles
Amgen
AstraZeneca
Bristol-Myers Squibb
Erasca
F. Hoffmann-La Roche
Huyabio International
Iovance Biotherapeutics
IO Biotech
Merck & Co. Inc.
Moderna Ina.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/joxd1o
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
